Company Overview
Kymera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company dedicated to discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. The company functions within the Healthcare sector, specifically the Biotechnology industry, where it leverages proprietary technology to target specific proteins involved in various diseases. As of the latest reporting period, the company maintains a market capitalization of $6.50B and employs 238 individuals, while reporting trailing twelve-month revenue of $39.21M. These financial figures indicate that Kymera holds a substantial market capitalization relative to its current revenue stream, a characteristic often observed in biotechnology firms where asset value and future pipeline potential significantly outweigh current sales performance. The disparity between the $6.50B valuation and the $39.21M in annual revenue underscores the market's pricing of the company's clinical-stage assets and intellectual property rather than its immediate cash-generating capabilities.
Financial Health
The company reported trailing twelve-month revenue of $39.21M, net income of $-311,351,008, and EBITDA of $-338,831,008, revealing a significant gap between top-line sales and bottom-line profitability that highlights a cost structure dominated by research, development, and operational expenses rather than commercial overhead. With free cash flow standing at $-136,041,248, the company is currently consuming cash reserves to fund its operations, which limits immediate financial flexibility but is typical for clinical-stage entities investing heavily in trial execution. The gross margin is reported as 0.0%, the operating margin is -3411.0%, and the profit margin is 0.0%; these figures collectively indicate that the company has not yet achieved a positive profit threshold and that costs are substantially exceeding revenues at a scale inconsistent with mature commercial businesses. On the balance sheet, Kymera holds $848.28M in cash against $82.25M in debt, resulting in a debt-to-equity ratio of 5.21, which suggests a highly leveraged position relative to equity but is partially mitigated by the substantial cash hoard available for debt servicing or future obligations. The current ratio stands at 10.47, indicating an extremely strong position regarding short-term liquidity where current assets vastly exceed current liabilities, providing a robust buffer against immediate payment obligations. Additionally, the return on equity is -25.8% and the return on assets is -15.9%, metrics that reveal that management effectiveness in generating positive returns is currently constrained by the negative earnings environment inherent to the clinical-stage development phase.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to the absence of net income, while the forward P/E is -19.81, a negative multiple that implies the market is not valuing the stock based on current or near-term earnings but rather on future expectations of profitability that have not yet materialized. The price-to-book ratio is 4.10, indicating that the market is pricing the company at a significant premium over its book value, reflecting high expectations for the successful development and commercialization of its drug candidates. Alternative valuation metrics such as the price-to-sales ratio of 165.68 and the EV/EBITDA of -16.91 suggest that investors are placing immense value on the potential of the pipeline rather than existing financial performance. The 52-week high is $103.00 and the 52-week low is $19.45, meaning the stock is trading within a wide range that captures significant volatility, with the current trading price positioned between these extremes based on recent market movements. The beta is 2.30, which signifies that the stock price is expected to be approximately 2.3 times as volatile as the broader market, exposing investors to substantial price swings in response to general market movements or sector-specific news.
Growth & Income
The revenue growth year-over-year is -61.2% and the earnings growth year-over-year is N/A, indicating that the company is currently experiencing a contraction in sales figures, likely due to the transition from commercial sales to clinical trials or the timing of revenue recognition in its pipeline. Since the earnings growth is N/A due to negative net income, the company is not growing earnings faster than revenue but is rather operating in a phase where earnings are negative while revenue fluctuates based on commercialization milestones. As a non-dividend payer, Kymera reports a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available earnings and cash flow back into research and development rather than distributing income to shareholders. The overall growth and income profile reflects a classic early-to-mid-stage biotechnology trajectory characterized by negative revenue growth in the current fiscal context, zero dividend distribution, and a reliance on capital markets or internal cash reserves to fund future expansion.